Arbutus Biopharma Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABUS Nasdaq 8731 http://www.arbutusbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arbutus Biopharma Corp

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update - Jun 25th, 2022 8:05 am
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022 - Jun 8th, 2022 6:05 am
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth - Jun 6th, 2022 6:45 pm
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus - Jun 6th, 2022 11:32 am
Arbutus to Participate in June Investor Conferences - Jun 2nd, 2022 11:30 am
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - May 26th, 2022 9:05 pm
Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds - May 20th, 2022 7:04 pm
Arbutus to Present at H.C. Wainwright Global Investment Conference - May 17th, 2022 11:30 am
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ - May 9th, 2022 12:16 pm
Party Time: Brokers Just Made Major Increases To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Earnings Forecasts - May 7th, 2022 12:05 pm
Arbutus Biopharma (ABUS) Q1 2022 Earnings Call Transcript - May 5th, 2022 6:30 pm
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2022 12:55 pm
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update - May 5th, 2022 11:30 am
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates - May 4th, 2022 10:55 pm
Arbutus Biopharma (NASDAQ:ABUS) investors are sitting on a loss of 33% if they invested a year ago - May 2nd, 2022 11:58 am
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update - Apr 21st, 2022 11:30 am
Pfizer's Canadian partner sues Arbutus Biopharma in Covid-19 vaccine patent dispute - Mar 24th, 2022 6:51 pm
UPDATE 1-Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine - Mar 18th, 2022 5:00 pm
Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine - Mar 18th, 2022 3:04 pm
This 1 New Threat Could Punish Moderna Stock - Mar 9th, 2022 1:00 pm